We also identified a number of genomic CNAs and mutations in novel genes that are enriched in or unique to LGSCs compared to SBTs, indicating that there are key identifiable molecular events underlying this transition, including novel mutations in EIF1AX and USP9X. These findings suggest the possibility of using patient-specific molecular events to improve treatment practices to best suit the clinical behaviour of the tumour, although larger studies with clinical follow-up are required. The gene discussed is USP9X; the disease is neoplasm.